PDS Biotechnology (NASDAQ:PDSB) Lowered to Sell Rating by StockNews.com

StockNews.com downgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a hold rating to a sell rating in a research note issued to investors on Saturday.

A number of other analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research report on Thursday, October 24th. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, PDS Biotechnology currently has a consensus rating of “Moderate Buy” and an average price target of $14.25.

PDS Biotechnology Price Performance

Shares of PDSB opened at $2.96 on Friday. The firm has a market cap of $108.99 million, a PE ratio of -2.66 and a beta of 1.93. PDS Biotechnology has a 52-week low of $2.53 and a 52-week high of $6.85. The business’s 50 day moving average price is $3.25 and its two-hundred day moving average price is $3.29. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same quarter last year, the firm earned ($0.37) earnings per share. On average, equities analysts anticipate that PDS Biotechnology will post -1.24 EPS for the current year.

Institutional Trading of PDS Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of PDSB. Vontobel Holding Ltd. raised its position in PDS Biotechnology by 233.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock valued at $153,000 after buying an additional 28,000 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of PDS Biotechnology in the second quarter valued at about $146,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of PDS Biotechnology during the second quarter valued at about $115,000. Squarepoint Ops LLC bought a new position in shares of PDS Biotechnology during the second quarter valued at about $120,000. Finally, Blair William & Co. IL boosted its holdings in PDS Biotechnology by 204.4% during the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after purchasing an additional 81,743 shares during the last quarter. 26.84% of the stock is owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.